Cooper makes contact lenses (CooperVision) and women's health devices like IUDs and fertility tools (CooperSurgical), selling to eye doctors and clinics worldwide.
Revenue is USD 4.09B annually, with gross margin at 60.67% and net margin at 9.16% for fiscal 2025. Contact lens sales are recurring, while surgical products are more one-off.
Brand trust and regulatory approvals in lenses and fertility create barriers, but Johnson & Johnson and Alcon compete fiercely, and recent quarterly losses signal pressure. Moat is eroding.
Sell (sector percentile 5) — value B-, growth D-, profitability B, momentum C, revisions D-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Multiple sources confirm earnings timing, market watches results
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
